- Home
- DVAX vs CDRE Comparison
DVAX vs CDRE Comparison
Compare DVAX & CDRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- CDRE
- Stock Information
- Founded
- DVAX 1996
- CDRE 2012
- Country
- DVAX United States
- CDRE United States
- Employees
- DVAX N/A
- CDRE N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- CDRE Industrial Specialties
- Sector
- DVAX Health Care
- CDRE Health Care
- Exchange
- DVAX Nasdaq
- CDRE Nasdaq
- Market Cap
- DVAX 1.3B
- CDRE 1.3B
- IPO Year
- DVAX 2004
- CDRE 2021
- Fundamental
- Price
- DVAX $11.36
- CDRE $33.91
- Analyst Decision
- DVAX Buy
- CDRE Buy
- Analyst Count
- DVAX 4
- CDRE 2
- Target Price
- DVAX $26.25
- CDRE $37.50
- AVG Volume (30 Days)
- DVAX 1.6M
- CDRE 229.6K
- Earning Date
- DVAX 08-05-2025
- CDRE 08-08-2025
- Dividend Yield
- DVAX N/A
- CDRE 1.12%
- EPS Growth
- DVAX N/A
- CDRE N/A
- EPS
- DVAX N/A
- CDRE 0.95
- Revenue
- DVAX $294,620,000.00
- CDRE $559,807,000.00
- Revenue This Year
- DVAX $21.18
- CDRE $13.31
- Revenue Next Year
- DVAX $16.83
- CDRE $7.96
- P/E Ratio
- DVAX N/A
- CDRE $35.79
- Revenue Growth
- DVAX 24.76
- CDRE 10.06
- 52 Week Low
- DVAX $9.22
- CDRE $27.07
- 52 Week High
- DVAX $14.63
- CDRE $40.28
- Technical
- Relative Strength Index (RSI)
- DVAX 66.09
- CDRE 58.57
- Support Level
- DVAX $10.38
- CDRE $32.15
- Resistance Level
- DVAX $11.48
- CDRE $34.38
- Average True Range (ATR)
- DVAX 0.30
- CDRE 0.77
- MACD
- DVAX 0.08
- CDRE 0.21
- Stochastic Oscillator
- DVAX 90.40
- CDRE 82.66
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.